Abliva AB (publ) (OTCMKTS:NEVPF – Get Rating) and DURECT (NASDAQ:DRRX – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.
Profitability
This table compares Abliva AB (publ) and DURECT's net margins, return on equity and return on assets.
Get Abliva AB (publ) alerts:| Net Margins | Return on Equity | Return on Assets | |
| Abliva AB (publ) | N/A | -159.15% | -120.99% |
| DURECT | -136.99% | -72.05% | -41.00% |
Analyst Recommendations
This is a summary of current ratings and price targets for Abliva AB (publ) and DURECT, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Abliva AB (publ) | 0 | 0 | 0 | 0 | N/A |
| DURECT | 0 | 0 | 0 | 0 | N/A |
Earnings and Valuation
This table compares Abliva AB (publ) and DURECT's revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Abliva AB (publ) | $20,000.00 | 201.51 | -$14.40 million | ($0.04) | -0.25 |
| DURECT | $13.98 million | 6.50 | -$36.26 million | ($0.14) | -2.85 |
Abliva AB (publ) has higher earnings, but lower revenue than DURECT. DURECT is trading at a lower price-to-earnings ratio than Abliva AB (publ), indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
43.1% of DURECT shares are held by institutional investors. 4.5% of DURECT shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
About Abliva AB (publ)
(Get Rating)
Abliva AB (publ) develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
About DURECT
(Get Rating)
DURECT Corp. focuses on advancing novel and potentially lifesaving investigational therapies derived from its Epigenetic Regulator Program. Its pipeline is called DUR-928, an endogenous sulfated oxysterol and an epigenetic regulator. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.
Receive News & Ratings for Abliva AB (publ) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abliva AB (publ) and related companies with MarketBeat.com's FREE daily email newsletter.